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Causative TP63mutations have been identified in five distinct human developmental disorders that are characterized
by various degrees of limb abnormalities, ectodermal dysplasia, and facial clefts. The distribution of mutations
over the various p63 protein domains and the structural and functional implications of these mutations establish
a clear genotype-phenotype correlation.
Introduction
Different syndromes can result from mutations in a single
gene. Quite often, these represent variations in severity,
as do the FGFR3 mutations, which cause hypochondro-
plasia, achondroplasia, and thanatophoric dysplasia.
More-divergent phenotypes may reflect the difference be-
tween gain-of-function and loss-of-function mutations,
as occurs with dominant brachydactyly type B and re-
cessive Robinow syndrome, which are caused by differ-
ent mutations of the ROR2 gene. Other examples of al-
lelic heterogeneity reflect a selective disruption of some
but not all the gene’s functions, as in the contrast, because
of an FGFR2mutation, between Apert and Crouzon syn-
dromes. For some genes there are multiple phenotypes
associated with mutations, but a clear genotype-pheno-
type correlation is lacking. A striking example of such
allelic heterogeneity are the GLI3 morphopathies: Greig
syndrome, Pallister-Hall syndrome, preaxial polydactyly
type IV, and postaxial polydactyly type A/B. We here re-
view the spectrum of p63 mutations that have been found
to underlie five human malformation syndromes: ectro-
dactyly–ectodermal dysplasia–clefting (EEC) syndrome
(MIM 604292), ankyloblepharon–ectodermal dysplasia–
clefting (AEC) syndrome (MIM 106260), limb-mammary
syndrome (LMS [MIM 603543]), acro-dermato-ungual-
lacrimal-tooth (ADULT) syndrome (MIM 103285),
and nonsyndromic split-hand/split-foot malformation
(SHFM). The localization and functional effects of the
mutations that underlie these syndromes establish a
striking genotype-phenotype correlation. Functional anal-
ysis of these mutations has provided valuable new insights
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into p63 protein structure and function and has provided
a basis for further dissection of molecular and cellular
pathways involving p63.
p63 Completes the p53/p73 Family
TP53 is the principal tumor-suppressor gene, being mu-
tated in 150% of human cancers (Levine 1997). The p53
protein is a key regulator of the cell cycle and, to prevent
damaged cells from becoming uncontrolled, allows com-
pletion of genomic-repair processes before the cell cycle
proceeds. For the past 20 years, p53 has continued to
surprise biomolecular researchers—publications on p53
that were listed in PubMed numbered 23,500 by January
2002. For this reason, the discovery of two genes related
to TP53, denoted as “TP73” and “TP63,” created con-
siderable excitement among tumor biologists (Jost et al.
1997; Kaghad et al. 1997; Schmale and Bamberger 1997;
Osada et al. 1998; Senoo et al. 1998; Trink et al. 1998;
Yang et al. 1998). It is now evident that TP73 and TP63
do not represent classical tumor-suppressor genes. Rather,
they act as key regulators in development—p73 in the
development of neuronal and pheromonal pathways
(Yang et al. 2000) and p63 in limb, epithelial, and cranio-
facial development (Mills et al. 1999; Yang et al. 1999).
Both p63 and p73 exhibit high amino acid identity with
p53, especially among their transactivation (TA) domains,
DNA-binding domain (DBD), and tetramerization (ISO)
domain (fig. 1). Unlike TP53, both TP63 and TP73 en-
code a number of isoforms (fig. 1). For both TP63 and
TP73, two transcription initiation sites were initially
described—one that would give rise to proteins containing
the TA domain (the TA isotypes) and another that would
give rise to proteins lacking this domain (theDN isotypes).
For TP63, additional transcripts were subsequently un-
covered in human and rodents, resulting from both the
use of at least four transcription initiation sites and
extensive alternative splicing at the 5′ end of the gene
(Schmale and Bamberger 1997; Yang et al. 1998; Hagi-
2 Am. J. Hum. Genet. 71:1–13, 2002
Figure 1 Structure of both TP63 and major protein isotypes. TP63 uses several transcription initiation sites (arrows) and extensive
alternative splicing, to generate a bewildering number of different mRNAs. For clarity, several alternative-splicing routes at the 5′ end of the
gene have not been indicated. Several protein domains can be distinguished; of these, the TA domains, the DBD, and the ISO domain are highly
homologous to the corresponding domains in p53. The SAM domain and the TID are not contained in the p53 protein. The capacity to
transactivate gene expression at a p53-responsive target is given for each of the indicated isotypes.
wara et al. 1999; Bamberger and Schmale 2001). Addi-
tionally, extensive alternative splicing is seen at the 3′ end
of the gene, resulting in three different C-termini for p63
and six for p73. For TP63, differential splicing of intron
8 creates additional variability in the final polypeptide
sequences (either GTKRP or A), but the functional sig-
nificance of this is not known. The extended 3′ coding
sequences of the a isotypes of TP63 and TP73 encode a
protein-protein–interaction motif that resembles the ster-
ile-a-motif (SAM) domain (Schultz et al. 1997; Bork and
Koonin 1998), which is not contained in p53. SAM
domains are small globular protein-protein–interaction
modules that are usually involved in homo- and hetero-
oligomerization with other SAM domains. It has been
demonstrated that the p63 and p73 SAM domains do not
oligomerize with one another (Chi et al. 1999), and the
interacting proteins still need to be identified. Besides these
major structural protein motifs, all members of the p53
family contain, in front of the DBD, proline-rich domains,
which are involved in pro-apoptotic activity and in the
capacity to activate target sequences (Zhu et al. 1999). A
second proline-rich region is located between the ISO and
SAM domains in p63 and p73 but not in p53. This pro-
line-rich domain is engaged in a physical association with
the YES-associated protein YAP. The binding of YAP to
p73a enhances its transcriptional activity at known p73-
responsive elements (Strano et al. 2001).
Differential Properties of the p63 Isotypes
From the primary sequence, one would predict that only
the p63 isotypes, which contain the acidic TA domain,
have transactivation activity, whereas the DN isotypes,
which lack this domain, do not have transactivation ac-
tivity. Although this is generally true, there are still some
exceptions to this rule. The largest p63 isotype, TA-
p63a, is unable to drive transcription on the optimized
p53-responsive element PG13, in contrast to TA-p63b
and TA-p63g (Yang et al. 1998) (fig. 1). This unexpected
lack of activity is caused by an inhibitory effect that is
contained within the a-specific C-terminal end. This in-
hibitory activity of the a tail also acts in trans toward
TA-p63b/g transcriptional activation, indicating that the
various p63 isotypes can have opposing properties. The
repressive activity has been mapped to the region, down-
stream from the SAM domain, that has been denoted as
the “transactivation inhibitory domain” (TID) (Ozaki et
al. 1999; V. Doetsch, personal communication). Tentative
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evidence suggests the presence of other regions within p63
that either promote or repress transactivation activity. For
example, the N-terminal TA-isotype variants that contain
an additional 39 amino acids (TA*) are unable to drive
transcription from the PG13 target sequence (Yang et al.
1998). Interestingly, activation of transcription can beme-
diated by p63 domains other than the canonical TA do-
main (Dohn et al. 2001; Strano et al. 2001; Duijf et al.
2002; also, see the “Genotype-Phenotype Correlations:
Molecular Dissection of the p63 Gene” section, below).
That all known and predicted isotypes contain the tetra-
merization domain creates an enormous potential for the
number of possible different p63 tetrameric complexes
that can be formed. Whether all possible complexes occur
in vivo remains to be demonstrated.
Regulation of p63 Protein Levels
Activation of the tumor suppressor p53 occurs in re-
sponse to a number of stressors, including DNAdamage,
hypoxia, oncogene activation, and UV irradiation (Vo-
gelstein et al. 2000). The main level of activation is me-
diated by posttranslational protein modifications, which
affect protein function and protein stability. UV-B-in-
duced DNA damage decreases levels of DN-p63a (a nat-
urally occurring dominant-negative form of the protein),
before increasing levels of p53 (Liefer et al. 2000; Yang
et al. 2002). Simultaneously, the levels of the transac-
tivating TA-p63 isoforms increase. The down-regulation
of dominant-negative DN-p63a, as well as the up-reg-
ulation that activates TA-p63 isoforms, may be a pre-
requisite for UV-induced apoptosis in skin (Liefer et al.
2000). This notion is supported by the recent observa-
tion that the transactivating TA-p63a (and TA-p73a)
isoforms are required for p53-dependent apoptosis
induced by DNA damage (Flores et al. 2002). The
role that this switch from inhibitory to activating p63
isoforms plays in normal skin development is further
discussed below (see “p63 in Mammalian Embryonic
Development”).
Little is known about p63 protein activation and
turnover. For p53, protein levels are tightly controlled
by the ubiquitin ligase MDM2, which promotes the
rapid degradation, by the proteasome pathway, of p53
(Haupt et al. 1997; Kubbutat et al. 1997). However,
conflicting results have been reported regarding the reg-
ulation, by ubiquitination through MDM2 and the re-
lated protein MDMX, of p63. For example, in three
different studies, MDM2 was shown to have either a
repressive effect, a stimulatory effect, or no effect at all
on p63-mediated transactivation (Kadakia et al. 2001;
Little and Jochemsen 2001; Calabro et al. 2002). Very
likely, these conflicting data are the result of variability
in both experimental design and the type of cell lines
that were used in these studies. One should be extremely
cautious in interpreting the results of these and similar
studies that are characterized by directive analyses based
on knowledge previously obtained for p53.
Upstream and Downstream from p63: Smad
and Jagged
A major breakthrough in our knowledge of upstream
factors that control TP63 expression was recently es-
tablished in a screen for genes that are positively regu-
lated by bone morphogenetic proteins (Bmps) during
zebrafish gastrulation. A differential display strategy
identified DN-p63a as a direct transcriptional target of
Bmp signaling (Bakkers et al. 2002). The early expres-
sion of DN-p63a appears to be driven by Smad4 and
Smad5, which are common mediators of Bmp signaling.
Accordingly, Smad4 and Smad5 binding sites are present
in the DN-p63 promoter (Bakkers et al. 2002). Bmps
promote the specification of ventral cell types in both
the mesoderm and the ectoderm, along the dorsoventral
axis of vertebrate embryos. In contrast, dorsal cell types,
such as the dorsal mesoderm and the neuroectoderm,
are formed unless they are instructed by Bmps not to
do so. This is known as the “neural default” model. The
zebrafish studies revealed that the effect that the Bmps
have on the counteraction of this neural default occurs
through DN-p63a, which acts as the neural repressor.
After the isolation of TP63, it was readily established
that the corresponding p63 proteins were able to bind
to an engineered p53-responsive element, PG13, and to
activate transcription of a downstream reporter gene
(Yang et al. 1998). Overexpression of p63 in mammalian
cell lines or in yeast can activate or repress the promoters
of several p53-responsive genes, including p21, Bax,
MDM2, GADD45, 14-3-3j, and EGFR (Osada et al.
1998; Shimada et al. 1999; Pochampally et al. 2000;
Dohn et al. 2001; Nishi et al. 2001; L. Guerrini, personal
communication). It is not clear, however, whether p53-
responsive genes are also regulated by p63 under phys-
iological conditions. Transfection experiments in kera-
tinocyte cell lines revealed that TA-p63 promotes the
expression of loricrin and involucrin, two markers of
terminal differentiation of epidermal cells (De Laurenzi
et al. 2000). Again, the physiological significance of this
observation is not known, although one may speculate
that p63 is involved in epidermal differentiation through
loricrin and involucrin. The first and only bona fide target
genes for p63 are Jagged1 (JAG1) and Jagged2 (JAG2),
which encode ligands for Notch receptors (Sasaki et al.
2002). A cDNAmicroarray analysis showed an increased
JAG1 and JAG2 expression in cell lines that were trans-
fected with adenoviral vectors expressing TA-p63g. The
physiological significance of this result was convincingly
demonstrated by chromatin-immunoprecipitation exper-
iments, which revealed binding of TA-p63g to promoter
4 Am. J. Hum. Genet. 71:1–13, 2002
elements of JAG1 in vivo. Also, co-culturing of Notch1-
expressing Jurkat cells with p63-transfected cells led
to an up-regulation of HES-1, a downstream target of
Notch signaling. This indicates that p63 can trigger the
Notch pathway in neighboring cells, possibly by induc-
tion of JAG1 and JAG2.Although JAG1mutations cause
Alagille syndrome in humans, no human disease has been
linked to JAG2 mutations. Interestingly, mice with ho-
mozygous inactivating Jag2 mutations have syndactyly
and defective craniofacial development, including cleft
palate (CP) (Sidow et al. 1997; Jiang et al. 1998). Much
work still needs to be done to elucidate other in vivo
targets of p63 transactivation and to determine the down-
stream effects of this transactivation.
p63 in Mammalian Embryonic Development
The spatiotemporal expression of the individual TP63
transcripts has not yet been explored in great detail. Im-
munohistochemical analyses of mouse embryos show
high p63 levels in epithelial cells, especially in progenitor
or stem-cell populations of epithelial tissues (Yang et al.
1998, 1999; Mills et al. 1999). The main isotype in these
cells is the dominant-negative DN-p63a isotype, which
likely acts in the maintenance of the proliferative capacity
of such cells (Yang et al. 1999). As these cells start to
differentiate, their DN-p63a levels gradually drop, and
the levels of TA-p63 increase. It thus appears that dom-
inant-negative DN-p63a is crucial for the maintenance of
the capacity of regenerative proliferation of epithelial stem
cells. Cells that no longer express DN-p63a lose this ca-
pacity and are committed to differentiation—and even-
tually reach terminal differentiation (Yang and McKeon
2002). Indeed, application of retinoic acid,whichprevents
degradation of DN-p63a, effectively blocks the differen-
tiation of skin epithelial stem cells (i.e., keratinocytes) in
culture (Bamberger et al. 2002).
In mouse embryos, TP63 expression is first evident in
nuclei of cells in the basal layer, which develop into the
progenitor cells of the epidermis and related derivatives,
such as hair and sweat glands. Basal cells of the cervix,
tongue, esophagus, mammary glands, prostate, and
urothelium also show high levels of p63. Early TP63
expression is further evident in ectodermal cells of the
limb buds and tail bud, branchial arches, and the oral
epithelium. In the developing limb bud, TP63 expres-
sion is restricted to the apical ectodermal ridge (AER),
a key determinant of limb-bud emergence and progres-
sion. Proper signaling along the antero-posterior axis
between the AER and the underlying mesoderm is cru-
cial for normal formation of the distal limb. The sites
of TP63 expression are well in line with the phenotypic
consequences of homozygous TP63 inactivation in
mice. These p63-deficient newborns exhibit striking
limb defects. The forelimbs are severely truncated, and
the hindlimbs are lacking altogether. The skin of the
knockout animals is absent, and newborn animals die
from dehydration shortly after birth. Other skin deriv-
atives, such as hair shafts and follicles are not present.
Finally, p63-deficient animals lack tooth primordia and
eyelids. Both the maxilla and the mandible are trun-
cated, and the secondary palate fails to close. Taken
together, the defects in p63-deficient mice present as
severe ectodermal dysplasia, abnormal limb develop-
ment, and facial dysmorphism.
A Family of EEC-like Syndromes
A group of multiple-congenital-anomaly syndromes is
characterized by EEC. The prototypic EEC syndrome has
this triad of features (Rudiger et al. 1970). EEC syndrome
frequently presents with other associated anomalies, such
as lacrimal-tract anomalies, urogenital anomalies, anal
atresia, and conductive hearing loss (Rudiger et al. 1970;
Rodini and Richieri-Costa 1990; Roelfsema and Cobben
1996). EEC syndrome is relatively common, with 1200
cases having been reported in the literature, and is well
known for having both variable expressivity and reduced
penetrance. A comparison of interfamilial and intrafam-
ilial variability in expressivity found significantly greater
interfamilial variability, suggesting that more than one
gene or allele might be involved (Roelfsema and Cobben
1996). Several autosomal dominant syndromes have been
described that share features with EEC (table 1), including
lacrimo-auricular-dental-digital (LADD) syndrome (MIM
149730) and LMS. Bamshad et al. (2000) proposed the
combination of the aforementioned four syndromes as
“LEAD syndrome” (named for limb, lacrimal, ecto-
dermal, and apocrine dysplasia). Other dominant syn-
dromes resemble the EEC syndrome in only one or two
of the cardinal features; for example, AEC syndrome
(also known as “Hay-Wells syndrome”) and Rapp-
Hodgkin syndrome (RHS [MIM 129400]) lack ectro-
dactyly, the ectrodactyly–cleft palate (ECP) syndrome
(MIM 129830) lacks ectodermal dysplasia, ADULT syn-
drome and the ectrodactyly–ectodermal dysplasia (EE)
syndrome (MIM 129810) lack cleft lip with or without
cleft palate (CL/P), and isolated SHFM is characterized
only by ectrodactyly.
TP63 Mutations: All in the Family
In 1999, linkage mapping of human EEC-like syndromes
identified a locus on 3q27, coinciding with the locali-
zation of TP63. This result, combined with the data
generated by the basic biological research on p63, sug-
gested that TP63was a strong positional candidate gene,
which led to the rapid identification of causative TP63
gene mutations in patients with EEC syndrome (Celli et
al. 1999). At the same time, these results established that
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Table 1















Split hand/split foot         
Fused digits, other   /      
Ectodermal:
Hair         
Skin         
Nail     /    
Teeth     /    
Lacrimal ducts         
Sweat glands         
Breast/nipple hypoplasia /        
Facial:
CL/P         
CP         
Microretrognathia         
Other:
Fused eyelid         
Supernumerary nipple /        
Poor saliva production         
Deformed ears/ear canals         
Hearing loss         
Extensive freckling         
Kidney hypoplasia         
Urethra/bladder         
Hypospadias         
NOTE.— p Consistent feature; p frequently observed; p occasionally observed; /p rarely observed; p never observed.
germline mutations in p63 are not associated with a
cancer-prone phenotype, as is the case for p53/Li-Frau-
meni syndrome. Moreover, the implication of p63 in
EEC syndrome paved the way to testing of the TP63
gene in the EEC-like syndromes, and by that, provided
insight into the molecular mechanisms underlying this
group of disorders (table 2).
EEC Syndrome
To date, 20 different heterozygous p63 mutations in 53
families with EEC syndrome are known (reported by Cel-
li et al. [1999], Ianakiev et al. [2000], Wessagowit et al.
[2000], Kosaki et al. [2001], and van Bokhoven et al.
[2001], as well as in the present article). Of the 50 families
for which the entire TP63-coding region was tested in our
laboratory, mutations were found in 49, indicating that
the p63 gene accounts for many, if not all, patients with
this syndrome. The patients with EEC syndromewho had
chromosomal abnormalities on 7q21-q22, overlapping
the SHFM1 locus (MIM183600), may be rare exceptions;
note that such patients rarely have the full EEC syndrome
phenotype (Scherer et al. 1994). Also note that many pa-
tients and small families with p63 mutations have all of
the clinical hallmarks of EEC syndrome except for CL/P,
suggesting that EE syndrome (Wallis 1988) is a variable
expression of the EEC syndrome. Twomutations, Y192C
and V202M, were observed only in patients with an EE
syndrome phenotype. All except one of the mutations in
families with EEC syndrome give rise to amino acid sub-
stitutions in the DBD that is common to all known p63
isoforms. The arginine codons 204, 227, 279, 280, and
304 were mutated in several unrelated patients. These
amino acids are crucially important for direct interactions
with DNA target sequences, and their mutation is highly
detrimental to DNA binding and transactivation activity.
Strikingly, most of the p63 germline mutations cor-
respond precisely to the somatic mutational hotspots in
the p53 gene in tumors (fig. 2). An exception is R227
in p63 (corresponding to R196 in p53, which is infre-
quently mutated in tumors), and the lack of mutations
at amino acids G276 and R313, which correspond to
the p53 mutational hotspots G245 and R282, respec-
tively (fig. 2). Two explanations, which are not mutually
exclusive, may account for the highly specific distribu-
tion of p63 mutations.
One explanation is the high mutability of the cor-
responding codons. Indeed, 46 of the 51 mutations in
families with EEC syndrome are CrT transitions at
CpG sites. Hence, the high mutability of 5-methylcy-
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Table 2




( )np 78 CpG Isleta Disorder(s) Reference(s)
Exon 3′:
N6H 1  ADULT syndrome Amiel et al. 2001
Exon 4:
G76W 1  LMS Authors’ unpublished data
Exon 5:
IVS4-2ArCb 1  SHFM van Bokhoven et al. 2001
Y163C 1  EEC syndrome Authors’ unpublished data
Y192C 2  EE syndrome Authors’ unpublished data
K193E 1  SHFM van Bokhoven et al. 2001
K194E 1  SHFM Ianakiev et al. 2000
V202M 1  EE syndrome Authors’ unpublished data
Exon 6:
R204W 6  EEC syndrome Celli et al. 1999, van Bokhoven et al. 2001
R204Q 4  EEC syndrome van Bokhoven et al. 2001, authors’ unpublished data
R227Q 4  EEC syndrome Authors’ unpublished data
Exon 7:
C269Y 1  EEC syndrome van Bokhoven et al. 2001
S272N 1  EEC syndrome Celli et al. 1999
C273Y 1  EEC syndrome Authors’ unpublished data
R279H 8  EEC syndrome Celli et al. 1999, Ianakiev et al. 2000, van Bokhoven et al.
2001, authors’ unpublished data
R279C 3  EEC syndrome Kosaki et al. 2001, van Bokhoven et al. 2001
R279Q 1  EEC syndrome van Bokhoven et al. 2001
R280C 5  EEC syndrome, SHFM Ianakiev et al. 2000, van Bokhoven et al. 2001, authors’
unpublished data
R280S 1  EEC syndrome van Bokhoven et al. 2001
R280H 2  EEC syndrome, SHFM van Bokhoven et al. 2001
R298Q 2  ADULT syndrome Duijf et al. 2002, authors’ unpublished data
Exon 8:
R304W 4  EEC syndrome Celli et al. 1999, Wessagowit et al. 2000, van Bokhoven
et al. 2001, authors’ unpublished data
R304Q 6  EEC syndrome Ianakiev et al. 2000, van Bokhoven et al. 2001
C306R 1  EEC syndrome Celli et al. 1999
C308S 1  EEC syndrome van Bokhoven et al. 2001
P309S 1  EEC syndrome van Bokhoven et al. 2001
D312H 1  EEC syndrome van Bokhoven et al. 2001
Exon 11:
IVS10-2ArGb 1  AEC syndrome Barrow et al., in press
Exon 13:
L518V 1  AEC syndrome McGrath et al. 2001
L518F 1  AEC syndrome McGrath et al. 2001
C526G 1  AEC syndrome McGrath et al. 2001
C526W 1  AEC syndrome McGrath et al. 2001
1689InsA 1  EEC syndrome Celli et al. 1999
1693-1694DelTT 1  LMS van Bokhoven et al. 2001
G534V 1  AEC syndrome McGrath et al. 2001
T537P 1  AEC syndrome McGrath et al. 2001
Q540L 1  AEC syndrome McGrath et al. 2001
I541T 2  AEC syndrome McGrath et al. 2001, authors’ unpublished data
Exon 14:
1859DelC 1  AEC syndrome Authors’ unpublished data
1860-1861DelAA 1  LMS van Bokhoven et al. 2001
Q634X 1  SHFM van Bokhoven et al. 2001
E639X 1  SHFM Authors’ unpublished data
a  p Mutation at a CpG site ( );  p mutation not at a CpG site ( ).np 45 np 33
b Intron mutation detected on analysis of the indicated exons.
tosine at CpG sites is a likely explanation for the high
proportion of recurrent mutations in EEC syndrome.
This would fit with the notion that the codons of the
p53 mutational hotspots G245 and R282 contain a
CpG, whereas the codons for the nonmutated p63 coun-
terparts G276 and R313 do not have a CpG site.
Another explanation, however, is that these recurrent
mutations reflect a specific pathogeneticmechanism. This
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Figure 2 Distribution of missense mutations in the DBDs of p53 and p63. Amino acid–sequence comparison of the DBDs of p53, p63,
and p73 reveals a high conservation, especially in the core domains (boxed). Within these core domains, amino acids that directly interact with
the DNA and amino acids that form the Zn-binding pocket of the protein are highlighted. The black bars on top represent the incidence of
somatic p53 mutations in tumors at the corresponding amino acids; the colored bars beneath the sequences represent the incidence of p63
mutations in the indicated human disorders. The p53-mutation spectrum is based on the IARC TP53 Mutation Database.
possibility is supported by the finding that a number of
different missense mutations occurred at amino acids
R204W/Q, R279C/H/Q, R280C/H/S, and R304W/Q, all
of which give rise to EEC syndrome. In contrast, mu-
tations elsewhere in the p63 protein yield phenotypically
distinguishable syndromes.
These two explanations are not mutually exclusive,
since disease-causing mutations may also be those of
DNA sites that are readily mutable. Regardless, it is
now clear that mutations in domains other than the
DBD give rise to related but clinically distinguishable
syndromes, suggesting that there is a specific relation-
ship between TP63 alleles and disease.
Analysis of the primary amino acid sequence (fig. 2)
and modeling of the structure of the p63DBDpredicted,
for the mutant p63 proteins in EEC syndrome, a general
disruptive effect on the DNA-binding capacity (Celli et
al. 1999). Support for this prediction was provided by
functional studies with mutant proteins in EEC syn-
drome. Mutant TA-p63g isotypes were no longer able
to promote the expression of a reporter gene, in contrast
to their wild-type counterpart. Also, mutant DN-p63a
was unable to compete with p53 for binding to this
target site. These data established that missense muta-
tions in EEC syndrome disrupt DNA binding for all p63
isotypes. The effects on transactivation will differ, how-
ever, depending on the sum of the transactivating TA-
p63g and the dominant-negative DN-p63a activities,
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thereby making it difficult to predict the net result on
transactivation in vivo. A single frameshift mutation
found in a patient with EEC syndrome did not disrupt
the DNA-binding capacity. Strikingly, this frameshift
mutation, which affects the p63a isotypes only, con-
ferred a gain of transactivation on the otherwise re-
pressive DN-p63a isotype (Celli et al. 1999).
AEC (Hay-Wells) Syndrome
AEC syndrome, which is also known as “Hay-Wells syn-
drome,” has little or no limb involvement but instead
includes ankyloblepharon, which is a partial or complete
fusion of the eyelids that is very rare in other EEC-like
syndromes (Hay and Wells 1976). Also, the ectodermal
dysplasia is much more pronounced in AEC than in the
other EEC-like syndromes. Severe infections of the scalp
are common during the first years of life. Mutations in
12 unrelated patients with AEC have been detected, and
10 of these mutations are missense mutations within the
SAM domain of p63 (McGrath et al. 2001). These mu-
tations are predicted to disrupt protein-protein inter-
actions, by either destroying the compact globular struc-
ture of the SAM domain or substituting amino acids
that are crucial for such interactions (McGrath et al.
2001). Further interpretation of the consequences of the
SAM-domain mutations is obscured by our ignorance
of the normal biological role of this domain. The mis-
sense mutations in AEC syndrome affect only the a iso-
types of p63, which behave as inhibitors of transacti-
vation. Transactivation studies did not reveal any
increase in activity for mutant TA-p63g, indicating that
the SAM-domain mutations do not relieve the intra-
molecular repressive activity. In contrast, cotransfections
of mutant DN-p63a with wild-type p53 or TA-p63g
revealed a clear decrease of intermolecular repressive ac-
tivity. Tentative evidence indicates that the effects of the
SAM-domain mutations varies for different isotypes and
at different DNA target sites (L. Guerrini, personal com-
munication). For the functional and developmental con-
sequences of these mutations to be better understood, it
will be necessary to identify the protein(s) interacting
with the SAM domain.
ADULT Syndrome
ADULT syndrome differs from EEC syndrome by the
absence of facial clefting in patients with the former
(Propping and Zerres 1993). Instead, these patients
show neurodermitic signs—namely, exfoliative derma-
titis of the digits—and excessive freckling. Linkage stud-
ies in one large German family indicated allelism with
EEC syndrome, and, indeed, a pathogenetic mutation,
R298Q, was found in the p63 gene (Propping et al.
2000; Duijf et al. 2002). The same R298Q mutation
was recently found in an unrelated Italian family with
ADULT syndrome. Another missense mutation was re-
ported in an isolated patient with features of ADULT
syndrome (Amiel et al. 2001). This mutation lies in exon
3′ and results in a substitution (N6H) that is specific to
the DN-p63 isotypes.
LMS
LMS differs from EEC syndrome in at least three re-
spects. First, mammary-gland and nipple hypoplasia are
consistent features of LMS but are only occasionally seen
in EEC syndrome. Second, patients with LMS do not
have the hair and skin defects that are seen in EEC syn-
drome. Third, whereas patients with LMS have CP (van
Bokhoven et al. 1999), those with EEC syndrome have
CL/P but never have CP only. Phenotypically, LMS is
most similar to ADULT syndrome (Propping et al.
2000). Three different mutations have been detected in
patients with LMS. Two isolated patients with an LMS
phenotype have, in exons 13 and 14, frameshift muta-
tions that result in truncations of the p63a protein.
Therefore, the abundant p63 product in epithelial cells
would be missing the TID. The third mutation was iden-
tified in the large Dutch family with LMS (van Bokhoven
et al. 1999). The mutation is in exon 4 and creates a
substitution (G76W) just upstream from the TA domain
(P. Duijf, personal communication).
SHFM
SHFM is genetically heterogeneous, and three loci have
previously been identified by linkage analysis and study
of SHFM1, on 7q21-q22; SHFM2 (MIM 313350), on
Xq26; and SHFM3 (MIM 600095), on 10q24. In two
affected families, SHFM chromosomal abnormalities did
not map to any of these established loci but instead
mapped to 3q27-q28, thereby indicating the existence
of a fourth locus (SHFM4 [MIM 605289]) (Ianakiev et
al. 2000). Causative TP63mutations were found in both
families. A subsequent analysis of a group of ∼50 un-
related patients with SHFM revealed fivemutations, sug-
gesting that p63 mutations account for ∼10% of these
cases (van Bokhoven et al. 2001). Five of the seven p63
mutations seen in patients with SHFM are unique to this
syndrome—namely, missense mutations K193E and
K194E, nonsense mutations Q634X and E639X, and
splice-site mutation IVS4-2ArC (which causes the in-
sertion of a proline residue at position 233). The two
aforementioned nonsense mutations create truncations
of eight and three amino acids, respectively, in the C-
terminal end of the a isotypes. This C-terminal domain
contains the repressive domain, and removal of the last
eight amino acids partially abolishes this repression (V.
Doetsch, personal communication). In addition, the last
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five amino acids, KEEGE, may form an endoplasmic
retention signal, suggesting that protein routing may
also be impaired. Two other mutations, both at the
same codon, have been found in both SHFM and EEC
syndrome—namely, R280C and R280H. This arginine,
like the lysines at positions 193 and 194, is not in direct
contact with the DNA, and mutation of these residues
probably induces more-subtle effects on the DNA-bind-
ing capacity of p63.
Involvement of p63 in Other EEC-like Syndromes
We and others have tested a number of patients with
LADD syndrome (Hollister et al. 1973; Amiel et al. 2001;
authors’ unpublished data). A nucleotide change that cre-
ates a P472T substitution was identified in an isolated
patient with LADD syndrome. Although this change was
not detected in 1250 individuals (185 healthy controls
and 78 patients with an EEC-like syndrome), it is likely
to reflect a polymorphism, since the healthy father was
also carrying the same change. Hence, it appears that p63
mutations do not account for LADD syndrome. The an-
ticipated involvement in other related conditions, such as
ECP syndrome and RHS (Rapp andHodgkin 1968;Opitz
et al. 1980), still needs to be established.
Genotype-Phenotype Correlations: Molecular
Dissection of the p63 Gene
The pattern of mutations in the five human disorders
linked to p63 reveals a remarkable specificity of the mo-
lecular defects in this gene and clinical consequences.
The clustering of mutations—in the DBD, for EEC syn-
drome, and in the SAM domain, for AEC syndrome—
establishes a clear genotype-phenotype correlation. Fur-
thermore, the mutations in ADULT syndrome, as well
as most of the mutations in LMS and SHFM, are dis-
tinctive to these syndromes.
A number of observations can be made from more-
detailed analysis of the pattern of TP63 mutations (fig.
3). First, it is notable that the truncating mutations are
all located in the C-terminal part of the protein. Hence,
all p63 mutations known to date leave the ISO domain
intact. This allows the formation of tetrameric complexes
between wild-type andmutant p63 proteins, which offers
an explanation for the dominant effect of p63mutations.
We have previously rejected haploinsufficiency as an ex-
planation for the disease mechanism, because patients
with a heterozygous deletion on3q27-q29, encompassing
the p63 gene, do not display signs of EEC syndrome
(Chitayat et al. 1996; van Bokhoven et al. 2001).
The genotype-phenotype comparison suggests that
there are further associations with regard to the occur-
rence of ectrodactyly and the type of facial clefting.
Ectrodactyly is only seen in combination with missense
mutations before or in the DBD of p63 or in combi-
nation with truncating mutations in the C-terminal part
of the protein. In contrast, missense mutations in the
C-terminal part are never associated with ectrodactyly.
A second remarkable phenomenon involves the type of
facial clefting. The facial clefts seen in conjunction with
missense mutations in the conserved part of the DBD
always involve the primary palate (CL/P), whereas mu-
tations toward the C-terminal end of p63 may either
involve the primary palate or the secondary palate (CP).
Also, the most N-terminal amino acid substitutions,
which are located outside the conserved regions of the
DBD, give rise to either CP or no clefting at all but
never CL/P. The distinction between CL/P and CP is
relevant, from both genetic and developmental points
of view (Fraser 1970; Ferguson 1988). Anatomically,
the primary palate and the secondary palate form in-
dependently of one another. Genetically, CL/P and CP
also appear to be distinct, since the mixture of these
types of facial clefting is rarely observed within families.
The Van der Woude and AEC syndromes are rare ex-
amples of mixture of embryological and genetic types
of facial clefting (CL/P vs. CP) (Schinzel and Klausler
1986). The pattern of mutations associated with ectro-
dactyly and with the type of facial clefting provides a
basis for our conceptual thinking about the normal and
abnormal activities, in developmental cascades, of p63.
The genotype-phenotype correlations are extended by
the mutations found in ADULT syndrome. Like most
mutations in EEC syndrome, the R298Q mutation in
ADULT syndrome causes an amino acid substitution in
the DBD (Duijf et al. 2002). Yet, this mutation is strik-
ingly different from the mutations in EEC syndrome,
since, on the basis of the structural model of the DBD,
the arginine at position 298 itself does not participate
in DNA binding. This prediction was supported by tran-
sactivation assays, which revealed no significant loss of
activity for TA-p63gR298Q, in sharp contrast to EEC-
associated mutations of the same p63 isotype (Duijf et
al. 2002). Although this result was predicted, an un-
expected finding was the exceptional high transactiva-
tion activity for mutant DN-p63gR298Q, because this iso-
form is usually inert in these assays, since it lacks the
canonical TA domain. We offer two explanations for
this gain of transactivation activity: (1) The mutation
creates a novel site for binding of a transcriptional coac-
tivator. (2) The mutation releases a second TA domain
(denoted as “TA2”) that is normally kept in an inactive
state. Although the first option is already less likely from
a mechanistic point of view, there is additional support
for the second possibility from studies in cell lines with
inducible p63 expression (Dohn et al. 2001). In the
present study, we provide evidence that there is, in the
N-terminal end of p63, a TA2 domain, encompassing
14 amino acids from the DN-specific end and 12 amino
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Figure 3 Distribution of mutations in p63, revealing a genotype-phenotype correlation. The approximate positions of truncatingmutations
(left) and amino acid changes (right) are indicated, together with the associated phenotype, with respect to the occurrence of ectrodactyly and
the type of facial clefting. (For discussion, see text.) DNA binding p DBD; ISO p ISO domain; SAM p SAM domain.
acids common to all isotypes (fig. 4). Thus, we suggest
that the R298Q mutation constitutively activates this
TA2 domain, either by the release of intramolecular
protein-protein interactions (fig. 4A) or by the abolition
of an interaction with a repressor molecule (fig. 4B).
Interestingly, the N6H mutation, found in another fam-
ily with ADULT syndrome, and the G76W mutation,
found in a family with LMS, map precisely within this
postulated TA2 domain (fig. 4C). The close juxtaposi-
tion of these two residues in the putative TA2 domain
of the DN isotypes may be relevant, in light of the phe-
notypic similarity between LMS and ADULT syndrome.
The finding that most of the mutations in SHFM are
unique for this condition further extends the genotype-
phenotype correlation. Notable exceptions to this re-
lationship are the R280H and R280C mutations, which
are found in both SHFM and EEC syndrome. Interest-
ingly, these two missense mutations and the two other
SHFM missense mutations, K193E and K194E, involve
amino acids that are not in direct contact with the DNA
(Ianakiev et al. 2000; P. Duijf, personal communica-
tion). Another exception to genotype-phenotype cor-
relation is provided by the frameshift mutations in the
a tail of p63. For example, the two frameshift mutations
in exon 13 predict similar truncations, but one of these
is associated with EEC syndrome, whereas the other
gives rise to LMS. Likewise, the exon 14 frameshift
mutations are almost identical at the molecular level,
van Bokhoven and Brunner: Splitting p63 11
Figure 4 A gain-of-function mutation in ADULT syndrome re-
veals a second TA domain (TA2) in p63. A and B, Models explaining
the gain-of-function effect that the R298Q mutation has on the DN-
p63g isotype, which normally does not posses transactivation. The
TA2 domain is normally kept in an inactive state, either because of
intramolecular interaction (A) or because of binding of another protein
(B). This inhibition is proposed to be released in patients with ADULT
syndrome because the R298Q mutation abolishes this protein-protein
interaction. DNA-BD p DBD; Iso p ISO domain; TA2 p TA2 do-
main. C, Position of TA2 domain, as determined by Dohn et al. (2001).
The TA2 domain consists of 14 amino acids specific to the DN isotypes
and 12 amino acids common to all p63 isotypes. Interestingly, another
ADULT-syndrome mutation and an LMS mutation both give rise to
amino acid substitutions within the TA2 domain. DNA binding p
DBD; Iso p ISO domain.
but one is seen in LMS, whereas the other is seen in
AEC syndrome. The variable outcome of these muta-
tions suggests the influence of additional genetic or en-
vironmental factors. Interestingly, within families, mu-
tation of the arginine at position 280 always has the
same phenotypic outcome—namely, either SHFM or
EEC syndrome—supporting the notion that genetic
modifiers or epigenetic factors have a modulatory effect.
Evidence for genetic modifiers is found in mice with
mutations in genes that are likely to be involved in p63
pathways. The limb phenotype of the dactylaplasia
(Dac) mouse, a model for human SHFM3, not only
requires mutation of the dactylin gene but also requires
homozygosity for an as-yet-unknown modifier allele
that has been denoted as “mDac” (Sidow et al. 1999).
Another fascinating example, in the syndactylism (sm)
mouse, is caused by a disruption of the p63 target gene
Jag2 (Sidow et al. 1997; Sasaki et al. 2002). The sm
phenotype is strongly modified by genetic background,
and several loci, acting as either enhancers or suppres-
sors, have been mapped (Sidow et al. 1997). One of
these, the suppressor locus on mouse chromosome 16,
is syntenic to human chromosome 3q27-q29 and en-
compasses the TP63 gene. TP63 may be a modifier of
the mutant JAG2 phenotype, and, by analogy, JAG2
may be a modifier of the mutant p63 phenotype. The
hypothesis that there are specific modifier genes can be
further pursued by molecular studies of large families
with a single TP63mutation. Other candidate modifiers
include (a) genes that are known to be mutated in hu-
man syndromes with features that overlap those of the
EEC syndrome or (b) genes that are active in genetic
programs that are governed by p63. For full compre-
hension of the normal and disrupted properties of the
complex array of p63 isotypes, it will be necessary to
identify those genes that act together with or in response
to p63. It is to be expected that some of these will be
found either to be modifiers of the spectrum of EEC-
like disorders or to underlie LADD syndrome or the
90% of cases of SHFM that lack TP63 mutations.
Acknowledgments
We are indebted to the members of the Nijmegen Human
Genetics laboratory—in particular, Pascal Duijf, Jacopo Celli,
and Ellen van Beusekom. The continuous support from and
discussions with our collaborators Frank McKeon, Annie Yang,
Volker Doetsch, and John McGrath is greatly appreciated. Spe-
cial thanks to Ben Hamel and Arie Smits for their studies of the
family with LMS. Finally, we would like to thank Hans Scheffer,
the many clinicians from other Institutes, and, most of all, the
patients, for their participation in the studies described. Work
in our laboratory is supported by grants from the Dutch Foun-
dation for Scientific Research (NWO 903-42-190).
Electronic-Database Information
Accession numbers and URLs for data presented herein are
as follows:
IARC TP53 Mutation Database, http://www.iarc.fr/p53/ (for
mutation frequencies in the TP53 gene)
Online Mendelian Inheritance in Man (OMIM), http://
www.ncbi.nlm.nih.gov/Omim/ (for EEC syndrome
[MIM 604292], LADD syndrome [MIM 149730],
ADULT syndrome [MIM 103285], LMS [MIM 603543],
AEC syndrome [MIM 106260], RHS [MIM 129400], ECP
syndrome [MIM 129830], EE syndrome [MIM 129810],
SHFM1 [MIM 183600], SHFM2 [MIM 313350], SHFM3
[MIM 600095], and SHFM4 [MIM 605289])
References
Amiel J, Bougeard G, Francannet C, Raclin V, Munnich A,
Lyonnet S, Frebourg T (2001) TP63 gene mutation in
ADULT syndrome. Eur J Hum Genet 9:642–645
Bakkers J, Hild M, Kramer C, Furutani-Seiki M, Hammer-
12 Am. J. Hum. Genet. 71:1–13, 2002
schmidt M (2002) Zebrafish DNp63 is a direct target of
Bmp signaling and encodes a transcriptional repressor
blocking neural specification in the ventral ectoderm. Dev
Cell 6:617–627
Bamberger C, Pollet D, Schmale H (2002) Retinoic acid in-
hibits downregulation of DNp63a expression during ter-
minal differentiation of human primary keratinocytes. J In-
vest Dermatol 118:133–138
Bamberger C, Schmale H (2001) Identification and tissue dis-
tribution of novel KET/p63 splice variants. FEBS Lett 501:
121–126
Bamshad M, Jorde LB, Carey JC (2000) Getting a LEAD on
EEC. Am J Med Genet 90:183–184
Barrow LL, van Bokhoven H, Daack-Hirsch S, Andersen T,
van Beersum SEC, Gorlin R, Murray JC. Analysis of the
p63 gene in classic EEC syndrome, related syndromes, and
nonsyndromic orofacial clefts. Am J Med Genet (in press)
Bork P, Koonin EV (1998) Predicting functions from pro-
tein sequences—where are the bottlenecks? Nat Genet 18:
313–318
Calabro V, Mansueto G, Parisi T, Vivo M, Calogero RA, La
Mantia G (2002) The human MDM2 oncoprotein increases
the transcriptional activity and the protein level of the p53
homolog p63. J Biol Chem 277:2674–2681
Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits AP,
Newbury-Ecob R, Hennekam RC, Van Buggenhout G, van
Haeringen A, Woods CG, van Essen AJ, de Waal R, Vriend
G, Haber DA, Yang A, McKeon F, Brunner HG, van Bokho-
ven H (1999) Heterozygous germline mutations in the p53 ho-
molog p63 are the cause of EEC syndrome. Cell 99:143–153
Chi SW, Ayed A, Arrowsmith CH (1999) Solution structure
of a conserved C-terminal domain of p73 with structural
homology to the SAM domain. EMBO J 18:4438–4445
Chitayat D, Babul R, Silver MM, Jay V, Teshima IE, Babyn
P, Becker LE (1996) Terminal deletion of the long arm of
chromosome 3 [46,XX,del(3)(q27rqter)]. Am J Med Genet
61:45–48
De Laurenzi V, Rossi A, Terrinoni A, Barcaroli D, Levrero
M, Costanzo A, Knight RA, Guerrieri P, Melino G (2000)
p63 and p73 transactivate differentiation gene promoters
in human keratinocytes. Biochem Biophys Res Commun
273:342–346
Dohn M, Zhang S, Chen X (2001) p63a and DNp63a can
induce cell cycle arrest and apoptosis and differentially reg-
ulate p53 target genes. Oncogene 20:3193–3205
Duijf PHG, Vanmolkot KRJ, Propping P, Friedl W, Krieger E,
McKeon F, Do¨tsch V, Brunner HG, van Bokhoven H (2002)
Gain-of-function mutation in ADULT syndrome reveals the
presence of a second transactivation domain in p63. Hum
Mol Genet 11:799–804
FergusonMW (1988) Palate development. Development Suppl
103:41–60
Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon
F, Jacks T (2002) p63 and p73 are required for p53-depen-
dent apoptosis in response to DNA damage. Nature 416:
560–564
Fraser FC (1970) The genetics of cleft lip and cleft palate. Am
J Hum Genet 22:336–352
Hagiwara K, McMenamin MG, Miura K, Harris CC (1999)
Mutational analysis of the p63/p73L/p51/p40/CUSP/KET
gene in human cancer cell lines using intronic primers. Can-
cer Res 59:4165–4169
Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes
the rapid degradation of p53. Nature 387:296–299
Hay RJ, Wells RS (1976) The syndrome of ankyloblepharon,
ectodermal defects and cleft lip and palate: an autosomal
dominant condition. Br J Dermatol 94:277–289
Hollister DW, Klein SH, De Jager HJ, Lachman RS, Rimoin
DL (1973) The lacrimo-auriculo-dento-digital syndrome. J
Pediatr 83:438–444
Ianakiev P, Kilpatrick MW, Toudjarska I, Basel D, Beighton P,
Tsipouras P (2000) Split-hand/split-foot malformation is
caused by mutations in the p63 gene on 3q27. Am J Hum
Genet 67:59–66
Jiang R, Lan Y, ChapmanHD, Shawber C, Norton CR, Serreze
DV,Weinmaster G, Gridley T (1998) Defects in limb, cranio-
facial, and thymic development in Jagged2 mutant mice.
Genes Dev 12:1046–1057
Jost CA, Marin MC, Kaelin WG Jr (1997) p73 is a human
p53-related protein that can induce apoptosis. Nature 389:
191–194 (erratum 399:817 [1999])
Kadakia M, Slader C, Berberich SJ (2001) Regulation of p63
function by Mdm2 and MdmX. DNA Cell Biol 20:321–330
Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent
A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P,
McKeon F, Caput D (1997) Monoallelically expressed gene
related to p53 at 1p36, a region frequently deleted in neu-
roblastoma and other human cancers. Cell 90:809–819
Kosaki R, Ohashi H, Yoshihashi H, Suzuki T, Kosaki K (2001)
A de novo mutation (R279C) in the P63 gene in a patient
with EEC syndrome. Clin Genet 60:314–315
Kubbutat M, Jones S, Vousden K (1997) Regulation of p53
stability by Mdm2. Nature 387:299–303
Levine AJ (1997) p53, the cellular gatekeeper for growth and
division. Cell 88:323–331
Liefer KM, Koster MI, Wang XJ, Yang A, McKeon F, Roop
DR (2000) Down-regulation of p63 is required for epider-
mal UV-B-induced apoptosis. Cancer Res 60:4016–4020
Little NA, Jochemsen AG (2001)Hdmx andMdm2 can repress
transcription activation by p53 but not by p63. Oncogene
20:4576–4580
McGrath JA, Duijf PH, Doetsch V, Irvine AD, de Waal R,
Vanmolkot KR, Wessagowit V, Kelly A, Atherton DJ, Grif-
fiths WA, Orlow SJ, van Haeringen A, Ausems MG, Yang
A, McKeon F, Bamshad MA, Brunner HG, Hamel BC, van
Bokhoven H (2001) Hay-Wells syndrome is caused by het-
erozygous missense mutations in the SAM domain of p63.
Hum Mol Genet 10:221–229
Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A
(1999) p63 is a p53 homologue required for limb and epi-
dermal morphogenesis. Nature 398:708–713
Nishi H, Senoo M, Nishi KH, Murphy B, Rikiyama T, Mat-
sumura Y, Habu S, Johnson AC (2001) p53 homologue p63
represses epidermal growth factor receptor expression. J Biol
Chem 276:41717–41724
Opitz JM, Frias JL, Cohen MM Jr (1980) The ECP syndrome,
another autosomal dominant cause of monodactylous ectro-
dactyly. Eur J Pediatr 133:217–220
Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R,
Katoh I, Ikawa Y, Nimura Y, Nakagawara A, Obinata M,
van Bokhoven and Brunner: Splitting p63 13
Ikawa S (1998) Cloning and functional analysis of human
p51, which structurally and functionally resembles p53. Nat
Med 4:839–843
Ozaki T, Naka M, Takada N, Tada M, Sakiyama S, Naka-
gawara A (1999) Deletion of the COOH-terminal region of
p73a enhances both its transactivation function and DNA-
binding activity but inhibits induction of apoptosis in mam-
malian cells. Cancer Res 59:5902–5907
Pochampally R, Li C, Lu W, Chen L, Luftig R, Lin J, Chen J
(2000) Temperature-sensitive mutants of p53 homologs.
Biochem Biophys Res Commun 279:1001–1010
Propping P, Friedl W, Wienker TF, Uhlhaas S, Zerres K (2000)
ADULT syndrome allelic to limb mammary syndrome
(LMS)? Am J Med Genet 90:179–182
Propping P, Zerres K (1993) ADULT-syndrome: an autosomal-
dominant disorder with pigment anomalies, ectrodactyly, nail
dysplasia, and hypodontia. Am J Med Genet 45:642–648
Rapp RS, Hodgkin WE (1968) Anhidrotic ectodermal dys-
plasia: autosomal dominant inheritance with palate and
lip anomalies. J Med Genet 5:269–272
Rodini ES, Richieri-Costa A (1990) EEC syndrome: report on
20 new patients, clinical and genetic considerations. Am J
Med Genet 37:42–53
Roelfsema NM, Cobben JM (1996) The EEC syndrome: a
literature study. Clin Dysmorphol 5:115–127
Rudiger RA, Haase W, Passarge E (1970) Association of ectro-
dactyly, ectodermal dysplasia, and cleft lip-palate. Am J Dis
Child 120:160–163
Sasaki Y, Ishida S, Morimoto I, Yamashita T, Kojima T, Kihara
C, Tanaka T, Imai K, Nakamura Y, Tokino T (2002) The
p53 family member genes are involved in the Notch signal
pathway. J Biol Chem 277:719–724
Scherer SW, Poorkaj P, Massa H, Soder S, Allen T, Nunes M,
Geshuri D, Wong E, Belloni E, Little S (1994) Physical map-
ping of the split hand/split foot locus on chromosome 7 and
implication in syndromic ectrodactyly. Hum Mol Genet 3:
1345–1354
Schinzel A, Klausler M (1986) The Van der Woude syndrome
(dominantly inherited lip pits and clefts). J Med Genet 23:
291–294
Schmale H, Bamberger C (1997) A novel protein with
strong homology to the tumor suppressor p53. Oncogene
15:1363–1367
Schultz J, Ponting CP, Hofmann K, Bork P (1997) SAM as a
protein interaction domain involved in developmental reg-
ulation. Protein Sci 6:249–253
Senoo M, Seki N, Ohira M, Sugano S, Watanabe M, Inuzuka
S, Okamoto T, Tachibana M, Tanaka T, Shinkai Y, Kato H
(1998) A second p53-related protein, p73L, with high ho-
mology to p73. Biochem Biophys Res Commun 248:603–607
Shimada A, Kato S, Enjo K, Osada M, Ikawa Y, Kohno K,
Obinata M, Kanamaru R, Ikawa S, Ishioka C (1999) The
transcriptional activities of p53 and its homologue p51/p63:
similarities and differences. Cancer Res 59:2781–2786
Sidow A, Bulotsky MS, Kerrebrock AW, Birren BW, Altshuler
D, Jaenisch R, Johnson KR, Lander ES (1999) A novel mem-
ber of the F-box/WD40 gene family, encoding dactylin, is
disrupted in the mouse dactylaplasia mutant. Nat Genet 23:
104–107
Sidow A, Bulotsky MS, Kerrebrock AW, Bronson RT, Daly
MJ, Reeve MP, Hawkins TL, Birren BW, Jaenisch R, Lander
ES (1997) Serrate2 is disrupted in the mouse limb-devel-
opment mutant syndactylism. Nature 389:722–725
Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi
A, Oren M, Sudol M, Cesareni G, Blandino G (2001) Phys-
ical interaction with Yes-associated protein enhances p73
transcriptional activity. J Biol Chem 276:15164–15173
Trink B, Okami K, Wu L, Sriuranpong V, Jen J, Sidransky D
(1998) A new human p53 homologue. Nat Med 4:747–748
van Bokhoven H, Hamel BC, Bamshad M, Sangiorgi E, Gur-
rieri F, Duijf PH, Vanmolkot KR, van Beusekom E, van
Beersum SE, Celli J, Merkx GF, Tenconi R, Fryns JP, Verloes
A, Newbury-Ecob RA, Raas-Rotschild A, Majewski F, Bee-
mer FA, Janecke A, Chitayat D, Crisponi G, Kayserili H,
Yates JR, Neri G, Brunner HG (2001) p63 gene mutations
in EEC syndrome, limb-mammary syndrome, and isolated
split hand-split foot malformation suggest a genotype-phe-
notype correlation. Am J Hum Genet 69:481–492
van Bokhoven H, Jung M, Smits AP, van Beersum S, Schendorf
R, van Steensel M, Veenstra M, Tuerlings JH, Mariman EC,
Brunner HG, Wienker TF, Reis A, Ropers HH, Hamel BC
(1999) Limb mammary syndrome: a new genetic disorder
with mammary hypoplasia, ectrodactyly, and other hand/
foot anomalies maps to human chromosome 3q27. Am J
Hum Genet 64:538–546
Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 net-
work. Nature 408:307–310
Wallis CE (1988) Ectrodactyly (split-hand/split-foot) and ec-
todermal dysplasia with normal lip and palate in a four-
generation kindred. Clin Genet 34:252–257
Wessagowit V, Mellerio JE, Pembroke AC,McGrath JA (2000)
Heterozygous germline missense mutation in the p63 gene
underlying EEC syndrome. Clin Exp Dermatol 25:441–443
Yang A, Kaghad M, Caput D, McKeon F (2002) On the shoul-
ders of giants: p63, p73 and the rise of p53. Trends Genet
18:90–95
Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch
V, Andrews NC, Caput D, McKeon F (1998) p63, a p53
homolog at 3q27-29, encodes multiple products with trans-
activating, death-inducing, and dominant-negative activities.
Mol Cell 2:305–316
Yang A, McKeon F (2002) P63 and P73: P53 mimics, menaces
and more. Nat Rev Mol Cell Biol 1:199–207
Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson
RT, Tabin C, Sharpe A, Caput D, Crum C,McKeon F (1999)
p63 is essential for regenerative proliferation in limb, cranio-
facial and epithelial development. Nature 398:714–718
Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M,
Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon
F, Caput D (2000) p73-deficient mice have neurological,
pheromonal and inflammatory defects but lack spontaneous
tumours. Nature 404:99–103
Zhu J, Jiang J, Zhou W, Zhu K, Chen X (1999) Differential
regulation of cellular target genes by p53 devoid of the
PXXP motifs with impaired apoptotic activity. Oncogene
18:2149–2155
